A new cell-permeable peptide allows successful allogeneic islet transplantation in mice

Calcineurin inhibitors such as cyclosporine A and FK506 have been used for transplant therapy and treatment of autoimmune diseases. However, the inhibition of calcineurin outside the immune system has a number of side effects, including hyperglycemia. In the search for safer drugs, we developed a ce...

Full description

Saved in:
Bibliographic Details
Published inNature medicine Vol. 10; no. 3; pp. 305 - 309
Main Authors Noguchi, Hirofumi, Matsushita, Masayuki, Okitsu, Teru, Moriwaki, Akiyoshi, Tomizawa, Kazuhito, Kang, Sunghyun, Li, Sheng-Tian, Kobayashi, Naoya, Matsumoto, Shinichi, Tanaka, Koich, Tanaka, Noriaki, Matsui, Hideki
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.03.2004
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN1078-8956
1546-170X
DOI10.1038/nm994

Cover

More Information
Summary:Calcineurin inhibitors such as cyclosporine A and FK506 have been used for transplant therapy and treatment of autoimmune diseases. However, the inhibition of calcineurin outside the immune system has a number of side effects, including hyperglycemia. In the search for safer drugs, we developed a cell-permeable inhibitor of NFAT (nuclear factor of activated T cells) using the polyarginine peptide delivery system 1 , 2 . This peptide provided immunosuppression for fully mismatched islet allografts in mice. In addition, it did not affect insulin secretion, whereas FK506 caused a dose-dependent decrease in insulin secretion. Cell-permeable peptides can thus provide a new strategy for drug development and may eventually be useful clinically.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1078-8956
1546-170X
DOI:10.1038/nm994